PD Dr med Arnoud Templeton
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole
Leibowitz-Amit R, Sridhar S, Tannock I, Knox J, Alimohamed N, Vera-Badillo F, Templeton A, Atenafu E, Seah J, Joshua A. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. Eur J Cancer 2014; 50:2399-407.
16.07.2014Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole
16.07.2014Eur J Cancer 2014; 50:2399-407
Leibowitz-Amit Raya, Sridhar Srikala S, Tannock Ian F, Knox Jennifer J, Alimohamed Nimira, Vera-Badillo Francisco E, Templeton Arnoud, Atenafu Eshetu G, Seah Jo-An, Joshua Anthony M
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014; 120:3346-52.
03.07.2014Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
03.07.2014Cancer 2014; 120:3346-52
Templeton Arnoud, Tannock Ian F, de Bono Johann S, Attard Gerhardt, Vera-Badillo Francisco E, Leibowitz-Amit Raya, McNamara Mairead G, Omlin Aurelius, Pezaro Carmel, Amir Eitan
Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis
Vera-Badillo F, Napoleone M, Ocana A, Templeton A, Seruga B, Al-Mubarak M, AlHashem H, Tannock I, Amir E. Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2014; 146:235-44.
14.06.2014Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis
14.06.2014Breast Cancer Res Treat 2014; 146:235-44
Vera-Badillo Francisco E, Napoleone Marc, Ocana Alberto, Templeton Arnoud, Seruga Bostjan, Al-Mubarak Mustafa, AlHashem Hashem, Tannock Ian F, Amir Eitan
Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder
Hermanns T, Templeton A, Zlotta A, Fleshner N, Jewett M, Almatar A, Bhatt J, Richard P, Noon A, Yu J, Wei Y, Bhindi B, Kulkarni G. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer 2014; 111:444-51.
10.06.2014Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder
10.06.2014Br J Cancer 2014; 111:444-51
Hermanns T, Templeton Arnoud, Zlotta A R, Fleshner N E, Jewett M A S, Almatar A, Bhatt J R, Richard P O, Noon A P, Yu J, Wei Y, Bhindi B, Kulkarni G S
Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis
Vera-Badillo F, Escudier B, Tannock I, Knox J, Aneja P, de Gouveia P, Ocana A, Duran I, Templeton A, Amir E. Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. Eur Urol 2014
29.05.2014Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis
29.05.2014Eur Urol 2014
Vera-Badillo Francisco E, Escudier Bernard, Tannock Ian F, Knox Jennifer J, Aneja Priya, de Gouveia Paulo, Ocana Alberto, Duran Ignacio, Templeton Arnoud, Amir Eitan
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
Templeton A, Tannock I, Tran B, Knox J, Sonpavde G, Leibowitz-Amit R, Ocana A, Aneja P, Vera-Badillo F, Seruga B, McNamara M, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106:dju124.
29.05.2014Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
29.05.2014J Natl Cancer Inst 2014; 106:dju124
Templeton Arnoud, Tannock Ian F, Tran Ben, Knox Jennifer J, Sonpavde Guru, Leibowitz-Amit Raya, Ocana Alberto, Aneja Priya, Vera-Badillo Francisco E, Seruga Bostjan, McNamara Mairead G, Amir Eitan
Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis
Templeton A, Tannock I, Ocana A, Seruga B, Hermanns T, Vera-Badillo F, Al-Mubarak M, McNamara M, Ace O, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23:1204-12.
03.05.2014Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis
03.05.2014Cancer Epidemiol Biomarkers Prev 2014; 23:1204-12
Templeton Arnoud, Tannock Ian F, Ocana Alberto, Seruga Bostjan, Hermanns Thomas, Vera-Badillo Francisco E, Al-Mubarak Mustafa, McNamara Mairead G, Ace Olga, Amir Eitan
Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
Ocana A, Pandiella A, Seruga B, Cuenca-Lopez M, Diez-Gonzalez L, Corrales-Sanchez V, Templeton A, Al-Mubarak M, Vera-Badillo F, Amir E. Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. PloS one 2014; 9:e95219.
28.04.2014Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
28.04.2014PloS one 2014; 9:e95219
Ocana Alberto, Pandiella Atanasio, Seruga Bostjan, Cuenca-Lopez María D, Diez-Gonzalez Laura, Corrales-Sanchez Verónica, Templeton Arnoud, Al-Mubarak Mustafa, Vera-Badillo Francisco, Amir Eitan
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Templeton A, Ruhstaller T, Thürlimann B, Zaman K, von Moos R, Rochlitz C, Winterhalder R, von Rohr L, Müller A, Winkler A, Borner M, Dietrich D, Beyeler M, Hsu Schmitz S, Sun H, Surber C, Ribi K, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 2014; 23:244-9.
20.03.2014Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
20.03.2014Breast 2014; 23:244-9
Templeton Arnoud, Ruhstaller Thomas, Thürlimann Beat, Zaman Khalil, von Moos Roger, Rochlitz Christoph, Winterhalder Ralph C, von Rohr Lukas, Müller Andreas, Winkler Annette, Borner Markus, Dietrich Daniel, Beyeler Michael, Hsu Schmitz Shu-Fang, Sun Hong, Surber Christian, Ribi Karin, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer
Sonpavde G, Smith M, Lechuga M, Chow-Maneval E, Chen I, Paolini J, Wang S, Templeton A, Vardy J, Clarke S, Armstrong A, Pond G, Michaelson M. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2014; 12:317-24.
15.03.2014Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer
15.03.2014Clin Genitourin Cancer 2014; 12:317-24
Sonpavde Guru, Smith Matthew R, Lechuga Mariajose, Chow-Maneval Edna, Chen Isan, Paolini Jolanda, Wang Shaw-Ling, Templeton Arnoud, Vardy Janette L, Clarke Stephen J, Armstrong Andrew J, Pond Gregory R, Michaelson M Dror
Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer
McNamara M, Templeton A, Maganti M, Walter T, Horgan A, McKeever L, Min T, Amir E, Knox J. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer 2014; 50:1581-9.
11.03.2014Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer
11.03.2014Eur J Cancer 2014; 50:1581-9
McNamara M G, Templeton Arnoud, Maganti M, Walter T, Horgan A M, McKeever L, Min T, Amir E, Knox J J
Extended adjuvant tamoxifen for early breast cancer: a meta-analysis
Al-Mubarak M, Tibau A, Templeton A, Cescon D, Ocana A, Seruga B, Amir E. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PloS one 2014; 9:e88238.
20.02.2014Extended adjuvant tamoxifen for early breast cancer: a meta-analysis
20.02.2014PloS one 2014; 9:e88238
Al-Mubarak Mustafa, Tibau Ariadna, Templeton Arnoud, Cescon David W, Ocana Alberto, Seruga Bostjan, Amir Eitan
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression
McNamara M, Laperriere N, Millar B, Chung C, Bernstein M, Zadeh G, Templeton A, Jiang H, Lwin Z, Mason W. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J Neurooncol 2014; 117:147-52.
28.01.2014Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression
28.01.2014J Neurooncol 2014; 117:147-52
McNamara Mairead G, Laperriere Normand, Millar Barbara-Ann, Chung Caroline, Bernstein Mark, Zadeh Gelareh, Templeton Arnoud, Jiang Haiyan, Lwin Zarnie, Mason Warren P
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
Leibowitz-Amit R, de Bono J, Tannock I, Sridhar S, Knox J, Attard G, Seah J, Vera-Badillo F, Keizman D, Atenafu E, Pezaro C, Omlin A, Templeton A, Joshua A. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2014; 25:657-62.
23.01.2014Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
23.01.2014Ann Oncol 2014; 25:657-62
Leibowitz-Amit R, de Bono J S, Tannock I F, Sridhar S S, Knox J J, Attard G, Seah J-A, Vera-Badillo F, Keizman D, Atenafu E G, Pezaro C, Omlin Aurelius, Templeton Arnoud, Joshua A M
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)
Rothermundt C, Cathomas R, Rüschoff J, Schiess R, Endt K, Lui L, Pollak M, Bärtschi D, Strebel R, Winterhalder R, Templeton A, Hayoz S, Gillessen Sommer S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol 2014; 66:468-74.
04.01.2014Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)
04.01.2014Eur Urol 2014; 66:468-74
Rothermundt Christian, Cathomas Richard, Rüschoff Jan H, Schiess Ralph, Endt Kathrin, Lui Lillianne, Pollak Michael, Bärtschi Daniela, Strebel Räto T, Winterhalder Ralph, Templeton Arnoud, Hayoz Stefanie, Gillessen Sommer Silke
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
Vera-Badillo F, Ocana A, Tannock I, Seruga B, Al-Mubarak M, Bedard P, Diaz-Padilla I, de Gouveia P, Templeton A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2013; 106:djt319.
22.11.2013Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
22.11.2013J Natl Cancer Inst 2013; 106:djt319
Vera-Badillo Francisco E, Ocana Alberto, Tannock Ian F, Seruga Bostjan, Al-Mubarak Mustafa, Bedard Philippe L, Diaz-Padilla Ivan, de Gouveia Paulo, Templeton Arnoud, Amir Eitan
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
Templeton A, Amir E, Pond G, Joshua A, Sridhar S, Moore M, Knox J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F, Tannock I. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24:2972-7.
14.10.2013Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
14.10.2013Ann Oncol 2013; 24:2972-7
Templeton Arnoud, Amir E, Pond G R, Joshua A M, Sridhar S S, Moore M, Knox J J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F E, Tannock I F
Benefit and harms of new anti-cancer drugs
Vera-Badillo F, Al-Mubarak M, Templeton A, Amir E. Benefit and harms of new anti-cancer drugs. Curr Oncol Rep 2013; 15:270-5.
01.06.2013Benefit and harms of new anti-cancer drugs
01.06.2013Curr Oncol Rep 2013; 15:270-5
Vera-Badillo Francisco E, Al-Mubarak Mustafa, Templeton Arnoud, Amir Eitan
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.
06.04.2013Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
06.04.2013Eur Urol 2013; 64:150-8
Templeton Arnoud, Schiess Ralph, Wild Peter J, Rüschoff Jan H, Thalmann George, Dietrich Pierre-Yves, Aebersold Ruedi, Klingbiel Dirk, Gillessen Sommer Silke, Müller Beat, Winterhalder Ralph, Stenner Frank, Dutoit Valérie, Cathomas Richard, Rothermundt Christian, Bärtschi Daniela, Dröge Cornelia, Gautschi Oliver, Borner Markus, Fechter Eva, Swiss Group for Clinical Cancer Research (SAKK)
Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
Hochstrasser A, Benz G, Jörger M, Templeton A, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012; 58:84-88.
23.02.2012Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?
23.02.2012Chemotherapy 2012; 58:84-88
Hochstrasser Andreas, Benz Gabriel, Jörger Markus, Templeton Arnoud, Brutsche Martin, Früh Martin